부산대학교 도서관

In: Blood. (Blood, 10 October 2024, 144(15):1648)

Prabhala R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; VA Boston Healthcare System, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States.; Pierceall WE; Bristol Myers Squibb, Summit, NJ, United States.; Samur M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, MA, United States.; Potluri LB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Hong K; Bristol Myers Squibb, Summit, NJ, United States.; Peluso T; Bristol Myers Squibb, Summit, NJ, United States.; Talluri S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Wang A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Katiki A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Vangala SD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Buonopane M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Bade V; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Seah H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Krogman A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Derebail S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Fulciniti M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Lazo SB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Richardson P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States.; Anderson K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States.; Corre J; Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.; Avet-Loiseau H; Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.; Thakurta A; Bristol Myers Squibb, Summit, NJ, United States.; Oxford Centre for Translational Myeloma Research, Oxford, United Kingdom.; Munshi N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; VA Boston Healthcare System, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States.

Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

La Rocca, R; Fulciniti, M; Lakshmikanth, T; Mesuraca, M; Ali, TH; Mazzei, V; Amodio, N; Catalano, L; Rotoli, B; Ouerfelli, O; Grieco, M; Gulletta, E; Bond, HM; Morrone, G; Ferrone, S; Carbone, E

Journal of immunology (Baltimore, Md. : 1950). 182(8):4529-4537

Deng S; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.; Derebail S; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Weiler VJ; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Fong Ng J; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Maroto-Martin E; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Chatterjee M; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; VA Boston Healthcare System, Boston, MA.; Giorgetti G; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Chakraborty C; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Kalhotra P; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Du T; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Yao Y; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Blood Disease Institute, Key Laboratory of Bone Marrow Stem Cell, Xuzhou Medical University, Xuzhou, China.; Prabhala R; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Shammas M; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; VA Boston Healthcare System, Boston, MA.; Gulla A; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.; Aktas Samur A; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Samur MK; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Qiu L; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.; Tianjin Institutes of Health Science, Tianjin, China.; Anderson KC; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Fulciniti M; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Munshi NC; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; VA Boston Healthcare System, Boston, MA.

Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

Zhu D; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; Wang Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; Guangdong Provincial Key Laboratory of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangdong, China.; Zhao JJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; Calimeri T; Department of Experimental and Clinical Medicine, Magna Graecia University and Cancer Center, Catanzaro, Italy.; Meng J; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; Fourth Affiliated Hospital of Harbin Medical University, Heilongjiang, China.; Hideshima T; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; Jerome Lipper Multiple Myeloma Center, Dana- Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; Fulciniti M; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; Jerome Lipper Multiple Myeloma Center, Dana- Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; Kang Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.; Ficarro SB; Department of Cancer Biology and Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA.; Tai YT; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; Jerome Lipper Multiple Myeloma Center, Dana- Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; Hunter Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; McMilin D; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; Jerome Lipper Multiple Myeloma Center, Dana- Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; Tong H; Department of Cancer Biology and Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Mitsiades CS; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; Wu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; Treon SP; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; Dorfman DM; Department of Pathology, Brigham & Women's Hospital, Boston, Massachusetts, USA.; Pinkus G; Department of Pathology, Brigham & Women's Hospital, Boston, Massachusetts, USA.; Munshi NC; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; Jerome Lipper Multiple Myeloma Center, Dana- Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; Tassone P; Department of Experimental and Clinical Medicine, Magna Graecia University and Cancer Center, Catanzaro, Italy.; Marto JA; Department of Cancer Biology and Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA.; Anderson KC; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; Jerome Lipper Multiple Myeloma Center, Dana- Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; Carrasco RD; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA. ruben_carrasco@dfci.harvard.edu.; Department of Pathology, Brigham & Women's Hospital, Boston, Massachusetts, USA. ruben_carrasco@dfci.harvard.edu.

Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: PubMed not MEDLINE; MEDLINE

Gulla A; Department of Medical Oncology, Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia-IRCCS, Candiolo, Italy.; Morelli E; Department of Medical Oncology, Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia-IRCCS, Candiolo, Italy.; Johnstone M; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Turi M; Department of Medical Oncology, Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia-IRCCS, Candiolo, Italy.; Samur MK; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA.; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA.; Botta C; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.; Cifric S; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Folino P; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Vinaixa D; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Northeastern University, Boston, MA.; Barello F; Department of Medical Oncology, Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia-IRCCS, Candiolo, Italy.; Clericuzio C; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Northeastern University, Boston, MA.; Favasuli VK; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Maisano D; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Talluri S; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; VA Boston Healthcare System, Boston, MA.; Prabhala R; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; VA Boston Healthcare System, Boston, MA.; Bianchi G; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.; Fulciniti M; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Wen K; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Kurata K; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.; Liu J; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Penailillo J; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Bragoni A; Department of Medical Oncology, Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia-IRCCS, Candiolo, Italy.; Department of Medical Sciences, University of Turin, Turin, Italy.; Sapino A; Department of Medical Oncology, Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia-IRCCS, Candiolo, Italy.; Department of Medical Sciences, University of Turin, Turin, Italy.; Richardson PG; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Chauhan D; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Carrasco RD; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.; Hideshima T; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Munshi NC; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; VA Boston Healthcare System, Boston, MA.; Anderson KC; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

In Blood 8 April 2010 115(14):2983-2983

Samur, M.K.; Aktas Samur, A.; Fulciniti, M.; Bazarbachi, A.H.; Tai, Y.-T.; Prabhala, R.; Alonso, A.; Sperling, A.S.; Anderson, K.C.; Munshi, N.C.; Campbell, T.; Hege, K.; Petrocca, F.; Kaiser, S.; Loiseau, H.A.

In: Nature Communications. (Nature Communications, 1 December 2021, 12(1))

Dutta D; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Liu J; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Wen K; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Kurata K; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Fulciniti M; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Gulla A; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Hideshima T; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. teru_hideshima@dfci.harvard.edu.; Anderson KC; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. kenneth_anderson@dfci.harvard.edu.

Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE

Gullà, A; Hideshima, T; Bianchi, G; Fulciniti, M; Kemal Samur, M; Qi, J; Tai, Y-T; Harada, T; Morelli, E; Amodio, N; Carrasco, R; Tagliaferri, P; Munshi, N C; Tassone, P; Anderson, K C

Leukemia. April, 2018, Vol. 32 Issue 4, p996